Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Journal of the National Cancer Institute - 19 Apr 2006

Thompson Ian M, Ankerst Donna Pauler, Chi Chen, Goodman Phyllis J, Tangen Catherine M, Lucia M Scott, Feng Ziding, Parnes Howard L, Coltman Charles A

Abstract excerpt

BACKGROUND: Prostate-specific antigen (PSA) testing is the primary method used to diagnose prostate cancer in the United States. Methods to integrate other risk factors associated with prostate cancer into individualized risk prediction are needed. We used prostate biopsy data from men who partic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy, Needle
Share to Black or African American
Share to Confounding Factors, Epidemiologic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Logistic Models

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms

Share to Randomized Controlled Trials as Topic

Share to Research Design

Source

Identifiers

PMID: 16622122
DOI: 10.1093/jnci/djj131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-16622122-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.PMID 16622122Read ↗

Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.Semantic proximity Read ↗

Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects.Semantic proximity Read ↗

Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study.Semantic proximity Read ↗

A simple-to-use method incorporating genomic markers into prostate cancer risk prediction tools facilitated future validation.Semantic proximity Read ↗

Defining high-risk prostate cancer: current status.Semantic proximity Read ↗

Development and validation of a simple prostate cancer risk prediction model based on age, family history, and polygenic risk.Semantic proximity Read ↗

Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection.Semantic proximity Read ↗

Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3).Semantic proximity Read ↗

Assessment of a Polygenic Risk Score in Screening for Prostate CancerSemantic proximity Read ↗

Precision intervention for prostate cancer: Re-evaluating who is at risk.Semantic proximity Read ↗

Risk factors, prevention and early detection of prostate cancer.Semantic proximity Read ↗

Improved prostate cancer prediction by combining Prostate-Specific Antigen (PSA) test results with Genetic Risk Scores (GRS/PRS)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.